Background: The members of Toll-like receptor (TLR) family are responsible for recognizing various molecular patterns associated with pathogens. Their expression is not confined to immune cells and have been detected in skin cells such as keratinocytes and melanocytes. As part of a generated response to pathogens, TLRs are involved in inducing inflammatory mediators to combat these threats. It is therefore not surprising that TLRs have been implicated in inflammatory skin diseases, including atopic dermatitis and psoriasis. Likewise, as key players in autoimmunity, they have been associated with a number of autoimmune diseases. Based on this, the role of TLRs in vitiligo could be suspected, but is yet to be clearly established.
Methods: In order to conduct a genetic association analysis, 30 SNPs were selected from TLR1-TLR8 and TLR10 regions to be genotyped in Estonian case-control cohort consisting of 139 vitiligo patients and 307 healthy control individuals. The patients were further analyzed in subgroups based on sex, age of onset, occurrence of vitiligo among relatives, extent of depigmented areas, vitiligo progression activity, appearance of Köbner's phenomenon, existence of halo naevi, and incidence of spontaneous repigmentation.
Results: The most notable finding came with SNP rs179020 situated in TLR7 gene, that was associated in entire vitiligo (Padj = 0.0065) and also several subgroup analyses. Other single marker and haplotype analyses pointed to TLR3, TLR4, and TLR10 genes.
Conclusions: This study investigated the genetic regions of nine TLR genes in relation to vitiligo susceptibility. The main results were the associations of TLR7 SNPs with vitiligo, while several other associations were obtained from the remaining TLR gene regions. This suggests that in addition to other inflammatory skin diseases, TLRs affect the development of vitiligo, thus making them interesting targets for future research.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563240 | PMC |
http://dx.doi.org/10.3389/fgene.2015.00278 | DOI Listing |
Biosci Microbiota Food Health
August 2024
Department of Pharmacy, Xiangyang key Laboratory of Special Preparation of Vitiligo, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China.
Vitiligo is a prevalent acquired depigmenting disease that is distinguished by the depletion of functional melanocytes and epidermal melanin. Despite significant advancements in comprehending vitiligo, the precise etiology and pathogenesis of the condition remain elusive. So far, the treatment of vitiligo is still one of the most difficult dermatological challenges.
View Article and Find Full Text PDFSci Rep
January 2025
Physics Department, Faculty of Sciences, TH-PPM Group, Beni-Suef University, Beni Suef, 62514, Egypt.
This theoretical work focuses on the application of Tamm resonance-based biosensing using a one-dimensional photonic crystal for detecting skin vitiligo, a condition caused by the loss of pigment in the body. This biosensor utilizes the interaction of light with the photonic structure to identify the specific biomarkers associated with vitiligo. The proposed structure is composed of prism/Ag/skin-sample/(GaP/PS)/glass.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Dermatology, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Vitiligo is a common long-term depigmenting skin disorder that is characterized by patches of skin losing their pigment. To evaluate serum/tissue levels of miR-16, 146a, 19b and 720 in vitiligo patients and healthy controls, also analyzing the correlations between all biomarkers to indicate whether those can be used to early diagnose vitiligo patients. Forty-subjects were included, divided into two equal groups, 20 healthy matched individuals and 20 vitiligo patients.
View Article and Find Full Text PDFHum Vaccin Immunother
December 2025
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Programmed cell death-1 (PD-1) inhibitors and programmed cell death ligand 1 (PD-L1) inhibitors are considered effective alternatives for the primary treatment of recurrent metastatic cancers. However, they can induce various adverse events affecting multiple organ systems, potentially diminishing patients' quality of life, and even leading to treatment interruptions. Adverse events related to PD-1/PD-L1 inhibitors differ from those associated with CTLA-4 inhibitors and are more commonly observed in the treatment of solid tumors.
View Article and Find Full Text PDFJ Cosmet Dermatol
January 2025
Department of Dermatology, The Johns Hopkins Hospital, Baltimore, Maryland, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!